生物科技股诺瓦瓦克斯医药(NVAX)今日在美股盘中出现大涨,最高上涨17.53%,报收于13.09美元,成为市场焦点。引发这一股价大涨的利好消息是该公司更新后的新冠疫苗在美国获准上市,将进入当地市场销售。
此前,诺瓦瓦克斯医药的初版新冠疫苗已在全球多国地区上市销售。经过更新的最新版本疫苗产品,不仅提升了对新冠病毒变异株的预防效力,而且扩大了适用人群至12岁及以上,以满足不同年龄人群的需求。
虽然新冠疫情已远离高峰期,但公众对预防性疫苗的需求依然存在。作为一家专业的疫苗研发企业,诺瓦瓦克斯医药一直致力于疫苗的持续更新迭代,保持产品的实用性与针对性,并着力扩大产能以满足全球市场需求。分析人士认为,该公司新冠疫苗在美国的上市获批,有望进一步推动公司在疫苗领域内的全球布局,提升其整体运营业绩,因此刺激了股价大涨。但同时投资者也需关注产品后续的市场销售情况,以及疫情发展带来的不确定因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.